flumazenil
benzodiazepine antagonist· Brands: Anexate, RomaziconIV
Mechanism of action
Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. It reverses the central nervous system depressant effects of benzodiazepines by displacing them from the receptor, but it does not directly activate the receptor or enhance GABAergic transmission. Its action is dose-dependent and can be overcome by higher concentrations of benzodiazepine.
Pharmacokinetics
Flumazenil is administered intravenously. After IV administration, it is rapidly distributed and has a short plasma half-life of about 1 hour. It is extensively metabolised in the liver, primarily by CYP3A4, to inactive metabolites. Less than 1% is excreted unchanged in urine. The onset of action is usually within 1-2 minutes, and peak effect occurs at approximately 5 minutes after administration. Because of its short half-life, sedation may recur after initial reversal, especially after long-acting benzodiazepines.
Indications & dosing
Reversal of benzodiazepine-induced sedation
Give initial 0.2 mg over 15 seconds; if required, repeat 0.3 mg and then 0.5 mg at 1-minute intervals. Maximum total 1 mg.
- adult · IV: 0.2–0.5 mg every 1 min PRN · Give initial 0.2 mg over 15 seconds; if required, repeat 0.3 mg and then 0.5 mg at 1-minute intervals. Maximum total 1 mg.
Benzodiazepine overdose
Initial dose 0.2 mg IV, then repeated doses (0.3 mg, 0.5 mg) at 1-minute intervals up to a maximum total of 2 mg. Caution in benzodiazepine-dependent patients.
- adult · IV: 0.2–0.5 mg every 1 min PRN · Initial dose 0.2 mg IV, then repeated doses (0.3 mg, 0.5 mg) at 1-minute intervals up to a maximum total of 2 mg. Caution in benzodiazepine-dependent patients.
Hepatic encephalopathyoff-label
Off-label use; may be given as a single intravenous bolus in selected patients. Evidence is limited.
- adult · IV: 0.5–1 mg stat · Off-label use; may be given as a single intravenous bolus in selected patients. Evidence is limited.
Contraindications & precautions
- Hypersensitivity to flumazenil or any component of the formulation · Avoid in patients with known allergy to flumazenil.
- Mixed overdose with benzodiazepines and tricyclic antidepressants · Risk of inducing seizures and arrhythmias.
- Severe head injury or raised intracranial pressure · Flumazenil may increase intracranial pressure.
- Status epilepticus or uncontrolled seizure disorder · Flumazenil may precipitate seizures.
- Use with caution in patients with a history of epilepsy or seizures, as flumazenil may lower the seizure threshold.
- Monitor for resedation after reversal, as flumazenil has a shorter duration of action than many benzodiazepines.
- Use caution in patients with hepatic impairment, as flumazenil is metabolised in the liver.
- Avoid in patients with long-term benzodiazepine dependence, as it can precipitate severe withdrawal syndromes.
- Ensure adequate airway protection and ventilation support are available, as flumazenil does not treat underlying causes of benzodiazepine overdose.
Adverse effects
- Nausea and vomiting
- Dizziness
- Agitation and anxiety
- Seizuresserious
- Cardiac arrhythmiasserious
- Withdrawal reactions (e.g., tremor, hallucinations)serious
Renal & hepatic adjustment
- Hepatic impairment (moderate): No specific dose adjustment; use with caution as clearance may be reduced.
- Hepatic impairment (severe): Use with extreme caution; consider reduced dosing and careful monitoring.
Monitoring, pregnancy & toxicity
- Respiratory rate · During and after administration
- Oxygen saturation · Continuously until fully awake
- Blood pressure · During and after administration
- Heart rate · During and after administration
- Level of consciousness · Frequently to assess resedation
- Signs of benzodiazepine withdrawal · Monitor for agitation, tremors, seizures
- Pregnancy: Not recommended during pregnancy unless the potential benefit justifies the risk, as flumazenil may precipitate withdrawal in the mother and fetus.
- Toxicity: Seizures, especially in patients with benzodiazepine dependence or tricyclic antidepressant overdose · Administer standard anticonvulsants, support breathing and circulation.
- Toxicity: Cardiac arrhythmias and conduction disturbances · Monitor ECG, treat per arrhythmia protocol.
- Toxicity: Agitation, anxiety, and withdrawal symptoms · Provide supportive care, consider benzodiazepines if withdrawal is severe.
Clinical notes
Flumazenil is indicated for the reversal of benzodiazepine sedation in anaesthesia and for the management of benzodiazepine overdose. It should be used with caution in patients with benzodiazepine dependence, as it can precipitate acute withdrawal seizures. It is also contraindicated in patients with significant tricyclic antidepressant overdose or in those with a known hypersensitivity. Monitor patients closely for resedation, and repeat doses may be necessary. Flumazenil does not reverse the effects of other CNS depressants or non-benzodiazepine GABAergic drugs. It should not be used as a substitute for supportive care in overdose.
Log in to read the full flumazenil monograph
A free account unlocks the complete drug reference, the interaction checker, prescription practice and every other learning tool.
BNF; local formulary